Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Down 18.6% in November

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 57,000 shares, a decrease of 18.6% from the October 31st total of 70,000 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average daily volume of 36,200 shares, the days-to-cover ratio is currently 1.6 days.

Marker Therapeutics Trading Up 9.7 %

MRKR stock traded up $0.31 during mid-day trading on Friday, hitting $3.50. 19,822 shares of the company were exchanged, compared to its average volume of 25,818. The business has a fifty day simple moving average of $3.35 and a 200-day simple moving average of $3.85. Marker Therapeutics has a 12-month low of $2.44 and a 12-month high of $6.16.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. boosted its stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned 0.78% of Marker Therapeutics worth $377,000 as of its most recent SEC filing. Institutional investors own 22.39% of the company’s stock.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH increased their target price on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.